IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$76.48 USD
+1.62 (2.16%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $76.46 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.48 USD
+1.62 (2.16%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $76.46 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
5 Cheap Breakout Stocks for Superb Returns
by Swarup Gupta
The technique identifies those stocks whose prices are fluctuating within a specific band.
TESARO Varubi IV Gets Complete Response Letter in the U.S.
by Zacks Equity Research
TESARO (TSRO) announced that it has received a Complete Response Letter from the FDA regarding its NDA for Varubi IV.
Gilead (GILD) HBV Drug Vemlidy Receives European Approval
by Zacks Equity Research
Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.
Top Ranked Momentum Stocks to Buy for December 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 19th: